Sysmex Beat Consensus Estimates

Sysmex (SSMXY) reported earnings of $0.09 per share on revenue of $819.98 million for the fiscal first quarter ended June 2026. The consensus earnings estimate was $0.07 per share. The company beat consensus estimates by 28.57% while revenue grew 12.04% on a year-over-year basis.

Sysmex Corporation is engaged in the development, manufacture, import, export and sale of clinical laboratory instruments, reagents and software used in -vitro diagnostics. It also provides clinical laboratory testing of blood, urine and other specimens. The company's product includes instruments and reagents diagnostics for hemostasis, immunochemistry, clinical chemistry, urinalysis and point-of-care testing. Its operating segment consists of Japan, Americas, EMEA, China and Asia Pacific. Sysmex Corporation is headquartered in Kobe, Japan.